Bio-Path Holdings, Inc. (BPTH)
USD 0.15
(0.0%)
USD 0.15
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.07 Million USD | -16.21% |
| 2022 | -13.83 Million USD | -32.56% |
| 2021 | -10.43 Million USD | 3.86% |
| 2020 | -10.85 Million USD | -27.64% |
| 2019 | -8.5 Million USD | 0.91% |
| 2018 | -8.58 Million USD | -22.21% |
| 2017 | -7.02 Million USD | -4.04% |
| 2016 | -6.75 Million USD | -23.47% |
| 2015 | -5.46 Million USD | -20.95% |
| 2014 | -4.51 Million USD | -38.39% |
| 2013 | -3.26 Million USD | -26.47% |
| 2012 | -2.58 Million USD | -9.27% |
| 2011 | -2.36 Million USD | -13.54% |
| 2010 | -2.08 Million USD | -5.67% |
| 2009 | -1.96 Million USD | 30.95% |
| 2008 | -2.85 Million USD | -5329.08% |
| 2007 | -52.54 Thousand USD | 64.47% |
| 2006 | -147.9 Thousand USD | -74.96% |
| 2005 | -84.53 Thousand USD | -27.57% |
| 2004 | -66.27 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.86 Million USD | 40.8% |
| 2024 Q1 | -3.15 Million USD | 6.38% |
| 2023 Q2 | -4.23 Million USD | 19.41% |
| 2023 Q4 | -3.37 Million USD | -5.41% |
| 2023 Q3 | -3.19 Million USD | 24.44% |
| 2023 Q1 | -5.25 Million USD | -33.15% |
| 2023 FY | -16.07 Million USD | -16.21% |
| 2022 Q1 | -3.35 Million USD | 18.39% |
| 2022 Q3 | -3.52 Million USD | -17.23% |
| 2022 Q2 | -3 Million USD | 10.51% |
| 2022 FY | -13.83 Million USD | -32.56% |
| 2022 Q4 | -3.94 Million USD | -11.98% |
| 2021 Q3 | -2.06 Million USD | -14.44% |
| 2021 FY | -10.43 Million USD | 3.86% |
| 2021 Q1 | -2.44 Million USD | 4.04% |
| 2021 Q2 | -1.8 Million USD | 26.11% |
| 2021 Q4 | -4.11 Million USD | -98.94% |
| 2020 Q2 | -2.04 Million USD | 38.63% |
| 2020 FY | -10.85 Million USD | -27.64% |
| 2020 Q1 | -3.32 Million USD | -39.14% |
| 2020 Q4 | -2.55 Million USD | 14.08% |
| 2020 Q3 | -2.96 Million USD | -45.49% |
| 2019 Q4 | -2.38 Million USD | -6.56% |
| 2019 Q2 | -2.45 Million USD | -62.43% |
| 2019 Q3 | -2.24 Million USD | 8.71% |
| 2019 FY | -8.5 Million USD | 0.91% |
| 2019 Q1 | -1.51 Million USD | 20.8% |
| 2018 Q3 | -3.08 Million USD | -83.72% |
| 2018 FY | -8.58 Million USD | -22.21% |
| 2018 Q4 | -1.9 Million USD | 38.04% |
| 2018 Q2 | -1.67 Million USD | 12.47% |
| 2018 Q1 | -1.91 Million USD | 11.58% |
| 2017 Q2 | -1.98 Million USD | -400.0% |
| 2017 Q4 | -2.16 Million USD | 12.41% |
| 2017 FY | -7.02 Million USD | -4.04% |
| 2017 Q1 | -397 Thousand USD | 71.04% |
| 2017 Q3 | -2.47 Million USD | -24.63% |
| 2016 FY | -6.75 Million USD | -23.47% |
| 2016 Q1 | -1.86 Million USD | -27.96% |
| 2016 Q2 | -1.94 Million USD | -4.02% |
| 2016 Q3 | -1.57 Million USD | 19.16% |
| 2016 Q4 | -1.37 Million USD | 12.68% |
| 2015 Q3 | -1.5 Million USD | -33.95% |
| 2015 Q1 | -1.37 Million USD | 13.97% |
| 2015 FY | -5.46 Million USD | -20.95% |
| 2015 Q2 | -1.12 Million USD | 18.12% |
| 2015 Q4 | -1.45 Million USD | 3.22% |
| 2014 Q3 | -1.14 Million USD | 9.49% |
| 2014 Q1 | -504.87 Thousand USD | 36.06% |
| 2014 Q2 | -1.26 Million USD | -151.3% |
| 2014 FY | -4.51 Million USD | -38.39% |
| 2014 Q4 | -1.59 Million USD | -39.14% |
| 2013 Q3 | -1.39 Million USD | -226.09% |
| 2013 FY | -3.26 Million USD | -26.47% |
| 2013 Q4 | -789.56 Thousand USD | 43.33% |
| 2013 Q2 | -427.24 Thousand USD | 34.87% |
| 2013 Q1 | -656 Thousand USD | -51.88% |
| 2012 FY | -2.58 Million USD | -9.27% |
| 2012 Q2 | -787.83 Thousand USD | -50.86% |
| 2012 Q1 | -522.22 Thousand USD | 35.05% |
| 2012 Q4 | -431.92 Thousand USD | 48.61% |
| 2012 Q3 | -840.55 Thousand USD | -6.69% |
| 2011 FY | -2.36 Million USD | -13.54% |
| 2011 Q4 | -804.05 Thousand USD | -59.59% |
| 2011 Q3 | -503.81 Thousand USD | -8.88% |
| 2011 Q1 | -592.72 Thousand USD | 10.52% |
| 2011 Q2 | -462.74 Thousand USD | 21.93% |
| 2010 Q1 | -490.94 Thousand USD | -13.43% |
| 2010 Q3 | -501.33 Thousand USD | -17.46% |
| 2010 Q4 | -662.4 Thousand USD | -32.13% |
| 2010 FY | -2.08 Million USD | -5.67% |
| 2010 Q2 | -426.81 Thousand USD | 13.06% |
| 2009 Q3 | -407.2 Thousand USD | 23.61% |
| 2009 FY | -1.96 Million USD | 30.95% |
| 2009 Q4 | -432.79 Thousand USD | -6.29% |
| 2009 Q2 | -533.04 Thousand USD | 10.67% |
| 2009 Q1 | -596.69 Thousand USD | 68.45% |
| 2008 Q4 | -1.89 Million USD | -691.16% |
| 2008 Q2 | -496.25 Thousand USD | -119.38% |
| 2008 FY | -2.85 Million USD | -5329.08% |
| 2008 Q3 | -239.04 Thousand USD | 51.83% |
| 2008 Q1 | -226.2 Thousand USD | -5.3% |
| 2007 Q4 | -214.81 Thousand USD | -802.6% |
| 2007 FY | -52.54 Thousand USD | 64.47% |
| 2007 Q1 | 43.95 Thousand USD | 233.33% |
| 2007 Q2 | -30.39 Thousand USD | -169.14% |
| 2007 Q3 | -23.8 Thousand USD | 21.69% |
| 2006 Q1 | -23.67 Thousand USD | -53.42% |
| 2006 Q4 | -32.97 Thousand USD | 0.51% |
| 2006 Q3 | -33.14 Thousand USD | 60.35% |
| 2006 Q2 | -83.58 Thousand USD | -253.06% |
| 2006 FY | -147.9 Thousand USD | -74.96% |
| 2005 Q2 | -39.71 Thousand USD | -92.95% |
| 2005 Q3 | -25.21 Thousand USD | 36.51% |
| 2005 FY | -84.53 Thousand USD | -27.57% |
| 2005 Q4 | -15.43 Thousand USD | 38.8% |
| 2005 Q1 | -20.58 Thousand USD | -49.14% |
| 2004 Q3 | -10.43 Thousand USD | 0.0% |
| 2004 FY | -66.27 Thousand USD | 0.0% |
| 2004 Q4 | -13.8 Thousand USD | -32.21% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -2011.581% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -86.26% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 47.712% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 87.046% |
| Better Therapeutics, Inc. | -39.76 Million USD | 59.562% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 14.778% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 12.515% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 55.103% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 55.419% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 85.961% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -615.131% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 78.492% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 72.787% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -168.492% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 24.495% |
| Molecular Templates, Inc. | -8.12 Million USD | -97.907% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -5.936% |
| NexImmune, Inc. | -32.34 Million USD | 50.291% |
| Orgenesis Inc. | -55.36 Million USD | 70.958% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 36.358% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -20508.329% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 12.093% |
| Scopus BioPharma Inc. | -11.6 Million USD | -38.486% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 97.193% |
| Statera Biopharma, Inc. | -174.4 Million USD | 90.781% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -348.105% |
| Trevena, Inc. | -40.28 Million USD | 60.093% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -28139.716% |
| Vaccinex, Inc. | -20.25 Million USD | 20.606% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -1260.108% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 68.51% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -106.733% |